コーパス検索結果 (１語後でソート)
通し番号をクリックするとPubMedの該当ページを表示します
1 ularly Interspaced Short Palindromic Repeats/CRISPR-associated protein 9).
2 terspaced short palindromic repeats (CRISPR)-CRISPR-associated protein 9.
3 terspaced short palindromic repeats (CRISPR)-CRISPR-associated protein 9.
4 interspaced short palindromic repeats)-Cas9 (CRISPR-associated protein 9) adenine base editing to cor
5 interspaced short palindromic repeats)/Cas9 (CRISPR-associated protein 9) are becoming major tools fo
6 ed regularly interspaced palindromic repeats/CRISPR-associated protein 9)-based DNA editing has rapid
7 nterspaced short palindromic repeat (CRISPR)-CRISPR associated protein 9 (Cas9) homology directed rep
8 terspaced short palindromic repeats (CRISPR)-CRISPR associated protein 9 (Cas9)-based therapeutic gen
9 terspaced short palindromic repeats (CRISPR)/CRISPR associated protein 9 (Cas9)-mediated mutagenesis
10 larly interspaced short palindromic repeats (CRISPR)-associated protein 9 (Cas9) guide RNAs and targe
11 d regularly interspaced palindromic repeats (CRISPR)-associated protein 9 (Cas9) has revolutionized t
12 ularly interspaced short palindromic repeat (CRISPR)-associated protein 9 (Cas9) system represents a
13 larly Interspaced Short Palindromic Repeats (CRISPR)-associated protein 9 (Cas9)-mediated gene-drive
14 ying an RNA-guided catalytically deactivated CRISPR-associated protein 9 (Cas9) anchored to a graphen
15 tial use of immune-orthogonal orthologues of CRISPR-associated protein 9 (Cas9) and adeno-associated
16 terspaced short palindromic repeats (CRISPR)/CRISPR-associated protein 9 (Cas9) and RNA-interference
17 geting capacity of catalytically deactivated CRISPR-associated protein 9 (Cas9) complexed with a spec
18 te (Hypa), and evolved (Evo) variants of the CRISPR-associated protein 9 (Cas9) endonuclease are crit
19 terspaced short palindromic repeats (CRISPR)-CRISPR-associated protein 9 (Cas9) functional analyses i
20 terspaced short palindromic repeats (CRISPR)/CRISPR-associated protein 9 (Cas9) gene editing approach
21 terspaced short palindromic repeats (CRISPR)/CRISPR-associated protein 9 (Cas9) gene editing approach
22 terspaced short palindromic repeats (CRISPR)-CRISPR-associated protein 9 (Cas9) gene-editing complex
23 nterspaced short palindromic repeat (CRISPR)/CRISPR-associated protein 9 (Cas9) genome-editing system
24 paced short palindromic repeats (CRISPR) and CRISPR-associated protein 9 (Cas9) genome-wide loss-of-f
25 though dual-delivery of pairs of CRISPR and CRISPR-associated protein 9 (Cas9) guiding RNAs into nor
26 erspersed short palindromic repeats (CRISPR)-CRISPR-associated protein 9 (Cas9) has reinvigorated int
27 terspaced short palindromic repeats (CRISPR)-CRISPR-associated protein 9 (Cas9) is a powerful tool fo
28 terspaced short palindromic repeats (CRISPR)/CRISPR-associated protein 9 (Cas9) mutagenesis in zebraf
29 terspaced Short Palindromic Repeats (CRISPR)-CRISPR-Associated Protein 9 (Cas9) nuclease gene editing
30 terspaced short palindromic repeats (CRISPR)/CRISPR-associated protein 9 (Cas9) ribonucleoprotein (RN
32 terspaced short palindromic repeats (CRISPR)/CRISPR-associated protein 9 (Cas9) screen to identify ge
33 nterspaced short palindromic repeat (CRISPR)/CRISPR-associated protein 9 (Cas9) system (CRISPR/Cas9)
34 arly interspaced, short palindromic repeats)/CRISPR-associated protein 9 (Cas9) system has emerged as
36 terspaced short palindromic repeats (CRISPR)-CRISPR-associated protein 9 (Cas9) systems and demonstra
37 nterspaced short palindromic repeat (CRISPR)/CRISPR-associated protein 9 (Cas9) technology has provid
38 terspaced short palindromic repeats (CRISPR)/CRISPR-associated protein 9 (Cas9) technology is a power
39 terspaced short palindromic repeats (CRISPR)-CRISPR-associated protein 9 (Cas9) with non-virally deli
40 terspaced short palindromic repeats (CRISPR)/CRISPR-associated protein 9 (Cas9), are viable and ferti
41 tically monitored genome-editing outcomes of CRISPR-associated protein 9 (Cas9), Cas9 nickases, catal
42 nterspaced short palindromic repeat (CRISPR)/CRISPR-associated protein 9 (Cas9), have provided resear
44 terspaced short palindromic repeats (CRISPR) CRISPR-associated protein 9 (Cas9), including specific g
45 terspaced short palindromic repeats (CRISPR)-CRISPR-associated protein 9 (Cas9)-based genome editing
46 terspaced short palindromic repeats (CRISPR)/CRISPR-associated protein 9 (Cas9)-engineered hESC-RUNX1
47 terspaced short palindromic repeats (CRISPR)/CRISPR-associated protein 9 (Cas9)-mediated editing in 2
48 ion of pharmacological inhibition and CRISPR/CRISPR-associated protein 9 (Cas9)-mediated gene editing
49 ific GSD-1a mouse model using somatic CRISPR/CRISPR-associated protein 9 (Cas9)-mediated gene editing
50 terspaced short palindromic repeats (CRISPR)-CRISPR-associated protein 9 (Cas9)-mediated gene editing
51 terspaced short palindromic repeats (CRISPR)-CRISPR-associated protein 9 (Cas9)-mediated screens usin
54 terspaced short palindromic repeats (CRISPR)/CRISPR-associated protein-9 (Cas9) technology, simultane
56 finger nucleases (ZFNs), genetically encoded CRISPR/associated protein 9 (Cas9) from Staphylococcus a
57 terspaced Short Palindromic Repeats (CRISPR)-CRISPR associated protein 9 (CRISPR-Cas9) genome editing
58 ularly interspaced short palindromic repeats/CRISPR associated protein 9 (CRISPR/Cas9) to scarlessly
59 egularly interspaced palindromic repeats and CRISPR-associated protein 9 (CRISPR-Cas9) gene-edited MU
60 ly Interspaced Short Palindromic Repeats and CRISPR-associated protein 9 (CRISPR-Cas9) genome editing
61 terspaced short palindromic repeats (CRISPR) CRISPR-associated protein 9 (CRISPR-Cas9) has garnered a
62 ularly interspaced short palindromic repeats CRISPR-associated protein 9 (CRISPR-Cas9), allow efficie
64 ularly interspaced short palindromic repeats/CRISPR-associated protein 9 (CRISPR/Cas9) system is emer
65 ularly interspaced short palindromic repeats/CRISPR-associated protein 9 (CRISPR/Cas9), immunofluores
66 ed regularly interspaced palindromic repeats/CRISPR-associated protein 9 (CRISPR/Cas9)-based technolo
68 larly interspaced short palindromic repeats (CRISPR)-associated protein 9 (dCas9) for efficient genet
69 s9-VP64 system consisting of the deactivated CRISPR-associated protein 9 (dCas9) fused with four tand
71 erspaced short palindromic repeats (CRISPR) /CRISPR associated protein 9-derived gid1 mutants were ge
72 egulatory elements used to express the Cas9 (CRISPR Associated protein 9) DNA nuclease and single gui
74 nterspaced short palindromic repeat (CRISPR)/CRISPR-associated protein 9 editing or with the GO-203 i
76 ularly interspaced short palindromic repeats/CRISPR-associated protein 9) endonucleases are short (<2
78 catalytically impaired Campylobacter jejuni CRISPR-associated protein 9-fused adenine base editor (C
80 presented in this study indicate that CRISPR/CRISPR-associated protein 9 gene editing of a cryptic po
81 f SMLR1 in the liver, we used somatic CRISPR/CRISPR-associated protein 9 gene editing to silence muri
82 ularly interspaced short palindromic repeats/CRISPR-associated protein 9 gene-editing system to delet
83 ularly interspaced short palindromic repeats/CRISPR associated protein 9) gene-editing technology to
84 terspaced short palindromic repeats (CRISPR)-CRISPR associated protein 9 genome editing technology to
85 nterspaced short palindromic repeat (CRISPR)/CRISPR-associated protein 9 genome editing and in vivo m
86 ularly interspaced short palindromic repeat (CRISPR) associated protein 9) genome editing technique i
87 ularly interspaced short palindromic repeats/CRISPR-associated protein 9) genome engineering technolo
88 ularly interspaced short palindromic repeats-CRISPR-associated protein 9) has been revolutionizing ge
89 ularly interspaced short palindromic repeats/CRISPR-associated protein 9 knockout of all three transc
90 interspaced short palindromic repeat)-Cas9 (CRISPR associated protein 9) knockout approaches to test
92 nterspersed short palindromic repeats)/Cas9 (CRISPR-associated protein 9)-mediated genome editing to
93 terspaced short palindromic repeats (CRISPR)/CRISPR-associated protein 9-mediated CD24 gene knockout
94 f nanoparticle-based CRISPR single-guide RNA/CRISPR-associated protein 9 mRNA against Cnpy2 has antit
95 nterspaced short palindromic repeat (CRISPR)/CRISPR associated protein 9 nuclease (Cas9)-mediated kno
96 larly interspaced short palindromic repeats (CRISPR)-associated protein-9 nuclease (Cas9), a method c
97 nterspaced short palindromic repeat (CRISPR)/CRISPR-associated protein 9 nuclease (Cas9) system depen
98 nterspaced short palindromic repeat (CRISPR)/CRISPR-associated protein 9 nuclease (Cas9) system is be
99 terspaced short palindromic repeats (CRISPR)/CRISPR-associated protein 9 nuclease (Cas9) technology o
100 terspaced short palindromic repeats (CRISPR)/CRISPR-associated protein-9 nuclease (Cas9) system, the
101 ularly interspaced short palindromic repeats/CRISPR-associated protein-9 nuclease (CRISPR/Cas9) syste
103 terspaced short palindromic repeats (CRISPR)/CRISPR-associated protein-9 nuclease to introduce the P9
105 terspaced short palindromic repeats (CRISPR)/CRISPR-associated protein 9 screening to investigate ven
107 ion activator-like effector proteins (TALE), CRISPR associated protein 9 (SpCas9) and the catalytical
108 terspaced short palindromic repeats (CRISPR)/CRISPR-associated protein 9 suppressed V-PPase activity,
109 ularly interspaced short palindromic repeats/CRISPR-associated protein 9 system that creates a DNA do
110 ularly interspaced short palindromic repeats-CRISPR associated protein 9) system to replace the RKLP
111 nterspersed short palindromic repeats)/Cas9 (CRISPR-associated protein 9) system has become the favor
112 interspaced short palindromic repeats)-Cas9 (CRISPR-associated protein 9) system, hold clinical poten
113 interspaced short palindromic repeat)-Cas9 (CRISPR-associated protein 9) system-that enable the dire
114 vere hemophilia A was generated using CRISPR/CRISPR-associated protein 9 targeting of exon 1 of the F
116 ly interspaced short palindromic repeats and CRISPR-associated protein 9) technology was delayed, whe
117 interspaced short palindromic repeats)/Cas9 (CRISPR-associated protein 9) that was modified to comple
118 ularly Interspaced Short Palindromic Repeats-CRISPR associated protein 9) to delete or modify candida
119 ularly-interspaced short palindromic repeats/CRISPR-associated protein 9) to correct the GBE1(102C>A)
120 rspaced short palindromic repeats) and Cas9 (CRISPR-associated protein 9) to generate fibroblast-spec
124 interspaced short palindromic repeats]/Cas9 [CRISPR-associated protein 9]) YES1 abrogation was also e